|
|
|
||
(State or other Jurisdiction of
Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of exchange on which registered
|
|
|
|
Nominee
|
Shares Voted For
|
Shares Withheld
|
Broker Non-Vote
|
|||
Michael Rice
|
19,779,345
|
171,656
|
0
|
|||
Raymond W. Cohen
|
19,459,325
|
491,676
|
0
|
|||
Andrew Hinson
|
19,193,703
|
757,298
|
0
|
|||
Joseph Schick
|
17,226,353
|
2,724,648
|
0
|
|||
Amy Duross
|
19,913,360
|
37,641
|
0
|
|||
Rachel Ellingson
|
19,804,907
|
146,094
|
0
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|||
14,145,547
|
5,782,635
|
22,819
|
0
|
Shares Voted For
|
Shares Voted Against
|
Shares Abstaining
|
Broker Non-Vote
|
|||
18,427,290
|
1,504,673
|
19,038
|
0
|
BioLife Solutions, Inc.
|
|||
Date: June 24, 2021
|
By:
|
/s/ Roderick de Greef
|
|
Roderick de Greef
|
|||
Chief Financial Officer
|
|||
Document And Entity Information |
Jun. 18, 2021 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | BIOLIFE SOLUTIONS, INC. |
Document, Type | 8-K |
Document, Period End Date | Jun. 18, 2021 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 001-36362 |
Entity, Tax Identification Number | 94-3076866 |
Entity, Address, Address Line One | 3303 Monte Villa Parkway |
Entity, Address, Address Line Two | Suite 310 |
Entity, Address, City or Town | Bothell |
Entity, Address, State or Province | WA |
Entity, Address, Postal Zip Code | 98021 |
City Area Code | 425 |
Local Phone Number | 402-1400 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | BioLife Solutions, Inc. Common Shares |
Trading Symbol | BLFS |
Security Exchange Name | NASDAQ |
Entity, Emerging Growth Company | false |
Amendment Flag | false |
Entity, Central Index Key | 0000834365 |
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end
_="%UYYZ--*892440#)'7_G7P&UK*VYU]=-9!
M%4\,MKW/?/GO4+U%/ #5BD.YOV;#"SF,=SL30YF:U2:KO8*=)EBXJN_GP5BX
MA#7?XRD+V_/J7D]E?&V9:Z*EJ/VO\90Z"%6M,?ZP\3[&;"0P_,I@QL=BYIGX
M=*%]VE@:O=?C1F5&6\\;E^(H4T>Y? ./&\N-A9J.&:3F5BQ*0KDP^1+Y(P4G
MROTUR2CD,,W"2@Q)-:NM5WL%.TTP/BC<"5GF1QVQZ)Q_P_KA0!.WUT"PD>'\5H.;Y#K,LC6(JQAKJ]0[_Q"M,?AV03B;4EFXD]!!:N4U
M%42Y*)-=,N-%(5E8WHA2]]MH2=(%:#+>,E@#Z\=] F*!PGP1?".7&%\KDNZT
M"T@INE:V?0SY6(7]9T86!?P*RQO0;X!="L*&^!1N_P"]